GlassScriptPhysician profile
James Ou Jin
NPI 1215900311
$13,237.47
in general payments reported to CMS, 2019-2025
72 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,098 · 2020: $665 · 2021: $1,969 · 2022: $912 · 2023: $4,055 · 2024: $2,324 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,956 · Education: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,956.12 |
| Education | $637.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,919.92 | 2019-2025 | Opdivo, Reblozyl, Eliquis |
| Merck Sharp & Dohme LLC | $775.61 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $760.09 | 2019-2024 | Erleada, Tecvayli, Darzalex |
| Astrazeneca Pharmaceuticals LP | $699.00 | 2019-2024 | Enhertu, Lynparza, Calquence |
| Pfizer INC. | $697.49 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $632.39 | 2019-2025 | |
| Amgen INC. | $584.18 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Celgene Corporation | $578.99 | 2019-2024 | Reblozyl, Opdualag, Pomalyst |
| Genentech USA, INC. | $499.64 | 2019-2024 | Venclexta, Tecentriq, Ocrevus |
| Astellas Pharma US INC | $448.17 | 2019-2025 | Xospata, Padcev |
| Genzyme Corporation | $441.60 | 2019-2023 | |
| Lilly USA, LLC | $336.23 | 2019-2024 | Jaypirca |
| Eisai INC. | $319.72 | 2019-2024 | |
| Seagen INC. | $299.81 | 2022-2023 | Padcev, Tukysa |
| Pharmacyclics LLC, An Abbvie Company | $282.92 | 2019-2021 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Jin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.